AstraZeneca’s $3.5 Billion Investment To Boost U.S. R&D And Manufacturing

AstraZeneca has unveiled a $3.5 billion investment in the United States, aimed at expanding its research and manufacturing capabilities by 2026. This investment includes $2 billion dedicated to creating over 1,000 high-skilled jobs, bolstering the U.S. economy. The company's expansion will feature an R&D center in Kendall Square, Cambridge, Massachusetts, biologics manufacturing facility in Maryland, new cell therapy manufacturing capacity on both the West & East Coasts and specialty manufacturing facilities in Texas. 

Pascal Soriot, Chief Executive Officer, AstraZeneca, said in a statement, “Our multibillion dollar investment reflects the attractiveness of the business environment together with the quality of talent and innovation capabilities here in the United States. By expanding our R&D and manufacturing footprint, we aim to enhance the development of cutting-edge therapies and support the United States leadership in healthcare innovation.”